Why switch from warfarin to NOACs?

  title={Why switch from warfarin to NOACs?},
  author={P. Verdecchia and F. Angeli and Adolfo Aita and C. Bartolini and G. Reboldi},
  journal={Internal and Emergency Medicine},
  • P. Verdecchia, F. Angeli, +2 authors G. Reboldi
  • Published 2016
  • Medicine
  • Internal and Emergency Medicine
  • Several patients with non-valvular atrial fibrillation treated with warfarin or other vitamin-K antagonists (VKA) might benefit from switching to an oral non vitamin-K antagonist anticoagulant (NOAC). In the absence of randomised comparative trials of switching to NOACs versus maintaining VKA treatment, several considerations argue in favour of a switching strategy. First, there is conclusive evidence that haemorrhagic strokes and intracranial bleedings are much fewer in number with NOACs than… CONTINUE READING
    37 Citations
    Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.
    • 2
    Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation
    • 2
    A Literature Review of Antithrombotic Therapy for Patients of Venous Thromboembolic Events with Comorbidity of Coronary Heart Disease.
    • 2


    Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
    • 4,630
    • PDF
    Edoxaban versus warfarin in patients with atrial fibrillation.
    • 3,032
    • PDF
    Dabigatran versus warfarin in patients with atrial fibrillation.
    • 2,870
    • PDF
    Perioperative management of patients who are receiving a novel oral anticoagulant
    • 38
    Net Clinical Benefit of Oral Anticoagulants: A Multiple Criteria Decision Analysis
    • 18
    • PDF